SG10201500274TA - Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists - Google Patents

Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists

Info

Publication number: SG10201500274TA
Authority: SG; Singapore
Prior art keywords: antagonists; variable domains; antibody variable; stable anti; tnfr1 polypeptides
Prior art date: 2009-10-27

Application number

SG10201500274TA

Inventor

Silva Inusha De

Armin Sepp

Adriaan Allart Stoop

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-10-27

Filing date

2010-10-25

Publication date

2015-03-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43382391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201500274T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-10-25 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2015-03-30 Publication of SG10201500274TA publication Critical patent/SG10201500274TA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

SG10201500274TA 2009-10-27 2010-10-25 Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists SG10201500274TA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US25523509P	2009-10-27	2009-10-27

Publications (1)

Publication Number	Publication Date
SG10201500274TA true SG10201500274TA (en)	2015-03-30

Family

ID=43382391

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG10201500274TA SG10201500274TA (en)	2009-10-27	2010-10-25	Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists

Country Status (27)

Country	Link
US (1)	US20150210767A1 (en)
EP (1)	EP2493504B1 (en)
JP (1)	JP2013507978A (en)
KR (1)	KR20120101417A (en)
CN (1)	CN102686239B (en)
AR (1)	AR078763A1 (en)
AU (1)	AU2010311640B2 (en)
BR (1)	BR112012010114A2 (en)
CA (1)	CA2777312A1 (en)
CL (1)	CL2012001055A1 (en)
CO (1)	CO6612254A2 (en)
CR (1)	CR20120197A (en)
DO (1)	DOP2012000113A (en)
EA (1)	EA022898B1 (en)
ES (1)	ES2552177T3 (en)
IL (1)	IL218860A0 (en)
MA (1)	MA33758B1 (en)
MX (1)	MX2012005024A (en)
NZ (1)	NZ599114A (en)
PE (1)	PE20121564A1 (en)
PH (1)	PH12012500826A1 (en)
SG (1)	SG10201500274TA (en)
TW (1)	TW201125877A (en)
UA (1)	UA107200C2 (en)
UY (1)	UY32969A (en)
WO (1)	WO2011051217A1 (en)
ZA (1)	ZA201203052B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EA022925B1 (en) *	2009-02-19	2016-03-31	Глаксо Груп Лимитед	Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists
WO2012172070A1 (en) *	2011-06-17	2012-12-20	Glaxo Group Limited	Tumour necrosis factor receptor 1 antagonists
CN104936973A (en) *	2013-01-31	2015-09-23	葛兰素集团有限公司	Method of producing a protein
WO2015104322A1 (en)	2014-01-09	2015-07-16	Glaxosmithkline Intellectual Property Development Limited	Treatment of inflammatory diseases with non-competitive tnfr1 antagonists
EP3440110B1 (en) *	2016-04-05	2022-01-26	Universität Stuttgart	Monovalent inhibitor of hutnfr1 interaction
KR20230078657A (en)	2020-08-27	2023-06-02	에노시 테라퓨틱스 코퍼레이션	Methods and compositions for treating autoimmune diseases and cancer
WO2022117569A1 (en)	2020-12-02	2022-06-09	Oncurious Nv	A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
CN114699533B (en) *	2022-05-06	2023-05-09	郑州大学	Preparation method and application of a nucleic acid aptamer and polypeptide cross-linked dual-target composite nucleic acid nanomedicine
WO2025049818A1 (en)	2023-08-29	2025-03-06	Enosi Therapeutics Corporation	Tnfr1 antagonists lacking agonist activity and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3883899T3 (en)	1987-03-18	1999-04-22	Sb2, Inc., Danville, Calif.	CHANGED ANTIBODIES.
GB8725529D0 (en)	1987-10-30	1987-12-02	Delta Biotechnology Ltd	Polypeptides
WO1989007142A1 (en)	1988-02-05	1989-08-10	Morrison Sherie L	Domain-modified constant region antibodies
ATE151110T1 (en)	1988-09-02	1997-04-15	Protein Eng Corp	PRODUCTION AND SELECTION OF RECOMBINANT PROTEINS WITH DIFFERENT BINDING SITES
ATE92107T1 (en)	1989-04-29	1993-08-15	Delta Biotechnology Ltd	N-TERMINAL FRAGMENTS OF HUMAN SERUM ALBUMIN-CONTAINING FUSION PROTEINS.
US5977307A (en)	1989-09-07	1999-11-02	Alkermes, Inc.	Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US6172197B1 (en)	1991-07-10	2001-01-09	Medical Research Council	Methods for producing members of specific binding pairs
WO1994026087A2 (en)	1993-05-14	1994-11-24	Connor Kim C O	Recombinant protein production and insect cell culture and process
EP0714409A1 (en)	1993-06-16	1996-06-05	Celltech Therapeutics Limited	Antibodies
ATE374815T1 (en)	1997-07-07	2007-10-15	Medical Res Council	METHOD OF INCREASE THE CONCENTRATION OF NUCLIC ACID MOLECULES
IL127127A0 (en)	1998-11-18	1999-09-22	Peptor Ltd	Small functional units of antibody heavy chain variable regions
CA2399388A1 (en)	2000-02-11	2001-08-16	Michael J. Lenardo	Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
WO2004081026A2 (en)	2003-06-30	2004-09-23	Domantis Limited	Polypeptides
DK1399484T3 (en)	2001-06-28	2010-11-08	Domantis Ltd	Double-specific ligand and its use
US20080108560A1 (en)	2002-03-05	2008-05-08	Eli Lilly And Company	Heterologous G-Csf Fusion Proteins
US20060002935A1 (en) *	2002-06-28	2006-01-05	Domantis Limited	Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US7696320B2 (en)	2004-08-24	2010-04-13	Domantis Limited	Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US9321832B2 (en) *	2002-06-28	2016-04-26	Domantis Limited	Ligand
EP2366718A3 (en)	2002-06-28	2012-05-02	Domantis Limited	Ligand
JP2006524036A (en)	2002-11-08	2006-10-26	アブリンクスエン．ヴェー．	Single domain antibodies targeting tumor necrosis factor alpha and uses thereof
GB0230203D0 (en)	2002-12-27	2003-02-05	Domantis Ltd	Fc fusion
JP2006523090A (en)	2002-12-27	2006-10-12	ドマンティスリミテッド	Bispecific single domain antibody specific for ligand and for ligand receptor
US20090005257A1 (en)	2003-05-14	2009-01-01	Jespers Laurent S	Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire
AU2005211725B2 (en)	2004-02-09	2010-07-15	Human Genome Sciences, Inc.	Albumin fusion proteins
CN101084014A (en) *	2004-10-08	2007-12-05	杜门蒂斯有限公司	Single domain antibodies against tnfr1 and methods of use therefor
GB0521621D0 (en)	2005-10-24	2005-11-30	Domantis Ltd	Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
GB0724331D0 (en)	2007-12-13	2008-01-23	Domantis Ltd	Compositions for pulmonary delivery
CA2683791A1 (en)	2007-06-06	2008-12-11	Domantis Limited	Polypeptides, antibody variable domains & antagonists
UY32450A (en) *	2009-02-19	2010-09-30	Glaxo Group Ltd	IMPROVED SERUM ANTI-ALBUMIN VARIANTS IMPROVED
EA022925B1 (en) *	2009-02-19	2016-03-31	Глаксо Груп Лимитед	Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists

2010
- 2010-10-25 PH PH1/2012/500826A patent/PH12012500826A1/en unknown
- 2010-10-25 CN CN201080059618.5A patent/CN102686239B/en not_active Expired - Fee Related
- 2010-10-25 BR BR112012010114A patent/BR112012010114A2/en not_active IP Right Cessation
- 2010-10-25 MX MX2012005024A patent/MX2012005024A/en not_active Application Discontinuation
- 2010-10-25 AU AU2010311640A patent/AU2010311640B2/en not_active Ceased
- 2010-10-25 NZ NZ599114A patent/NZ599114A/en not_active IP Right Cessation
- 2010-10-25 KR KR1020127013723A patent/KR20120101417A/en not_active Withdrawn
- 2010-10-25 TW TW099136369A patent/TW201125877A/en unknown
- 2010-10-25 WO PCT/EP2010/066046 patent/WO2011051217A1/en active Application Filing
- 2010-10-25 PE PE2012000560A patent/PE20121564A1/en not_active Application Discontinuation
- 2010-10-25 ES ES10774177.9T patent/ES2552177T3/en active Active
- 2010-10-25 SG SG10201500274TA patent/SG10201500274TA/en unknown
- 2010-10-25 EP EP10774177.9A patent/EP2493504B1/en active Active
- 2010-10-25 UY UY0001032969A patent/UY32969A/en not_active Application Discontinuation
- 2010-10-25 AR ARP100103911A patent/AR078763A1/en unknown
- 2010-10-25 UA UAA201204796A patent/UA107200C2/en unknown
- 2010-10-25 JP JP2012535767A patent/JP2013507978A/en active Pending
- 2010-10-25 CA CA2777312A patent/CA2777312A1/en not_active Abandoned
- 2010-10-25 EA EA201290172A patent/EA022898B1/en not_active IP Right Cessation
2012
- 2012-03-27 IL IL218860A patent/IL218860A0/en unknown
- 2012-03-29 CO CO12053463A patent/CO6612254A2/en unknown
- 2012-04-18 DO DO2012000113A patent/DOP2012000113A/en unknown
- 2012-04-23 CR CR20120197A patent/CR20120197A/en unknown
- 2012-04-25 ZA ZA2012/03052A patent/ZA201203052B/en unknown
- 2012-04-25 CL CL2012001055A patent/CL2012001055A1/en unknown
- 2012-05-18 MA MA34878A patent/MA33758B1/en unknown
2015
- 2015-04-09 US US14/682,176 patent/US20150210767A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EA201290172A1 (en)	2013-04-30
EP2493504B1 (en)	2015-10-07
UY32969A (en)	2011-05-31
PH12012500826A1 (en)	2013-01-07
IL218860A0 (en)	2012-06-28
AR078763A1 (en)	2011-11-30
WO2011051217A1 (en)	2011-05-05
MX2012005024A (en)	2012-09-07
JP2013507978A (en)	2013-03-07
TW201125877A (en)	2011-08-01
EA022898B1 (en)	2016-03-31
CR20120197A (en)	2012-06-22
KR20120101417A (en)	2012-09-13
ES2552177T3 (en)	2015-11-26
CN102686239B (en)	2016-02-03
EP2493504A1 (en)	2012-09-05
ZA201203052B (en)	2013-09-25
CN102686239A (en)	2012-09-19
CO6612254A2 (en)	2013-02-01
MA33758B1 (en)	2012-11-01
CL2012001055A1 (en)	2012-10-05
AU2010311640B2 (en)	2015-01-29
AU2010311640A1 (en)	2012-05-10
US20150210767A1 (en)	2015-07-30
NZ599114A (en)	2014-09-26
PE20121564A1 (en)	2012-11-29
CA2777312A1 (en)	2011-05-05
DOP2012000113A (en)	2012-08-15
UA107200C2 (en)	2014-12-10
BR112012010114A2 (en)	2017-08-08

Publication	Publication Date	Title
IL214648A0 (en)	2011-09-27	Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists
PT2162467E (en)	2015-10-29	Polypeptides, antibody variable domains & antagonists
IL201399A0 (en)	2010-05-31	Polypeptides, antibody variable domains and antagonists
IL218860A0 (en)	2012-06-28	Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists
ZA201103588B (en)	2012-01-25	Polypeptides,antibody variable domains & antagonists
IL252561A0 (en)	2017-07-31	Anti-siglec-15 antibodies, polynucleotides encoding the same, compositions comprising the same and uses thereof
HK1147269A1 (en)	2011-08-05	Anti-vegf antibodies vegf
IL232009A (en)	2015-11-30	Isolated, alpha4beta7 heterodimer specific antigen binding protein and various aspects related thereto
ZA201008993B (en)	2012-01-25	Anti-human interleukin-20 antibodies
EP2304440A4 (en)	2013-01-02	Novel monoclonal antibodies against hpv proteins
ZA201105323B (en)	2012-03-28	Agonists and antagonists of the sip5 receptor,and methods of uses thereof
EP2331579A4 (en)	2013-01-23	Monoclonal antibodies
IL214996A (en)	2016-10-31	Isolated antibody that binds a bmca polypeptide, a pharmaceutical composition comprising the same and uses thereof
IL218296A0 (en)	2012-04-30	Obpgplys/endolysin polypeptides, fusion proteins and compositions compriisng the same and uses thereof
AP2012006276A0 (en)	2012-06-30	New CCR2 receptor antagonists and uses thereof.
GB0708002D0 (en)	2007-06-06	Antibodies
SG10201601279SA (en)	2016-03-30	Monoclonal Antibody STRO-4
PL2354161T3 (en)	2016-01-29	Anti-nr10 antibody, and use thereof
GB0811298D0 (en)	2008-07-30	Characterising polypeptides
IL236236A (en)	2016-06-30	Fam26f polypeptide antibodies
IL200168A0 (en)	2010-04-15	Monoclonal anti-cxcl13 antibodies
IL218621A0 (en)	2012-05-31	Monoclonal antibodies
GB0718737D0 (en)	2007-11-07	Antibodies
IL203429A0 (en)	2011-07-31	Immunogenic polypeptides and monoclonal antibodies
SI2354161T1 (en)	2015-12-31	Anti-nr10 antibody, and use thereof